Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Depreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other financing activities Other financing activities Preferred Shares Issued Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Ratios

Atea Pharmaceuticals (AVIR) Capital Expenditures (2020 - 2022)

Atea Pharmaceuticals has reported Capital Expenditures over the past 2 years, most recently at $20000.0 for Q3 2022.

Quarterly results put Capital Expenditures at $20000.0 for Q3 2022, changed N/A from a year ago — trailing twelve months through Dec 2022 was $1.9 million (changed N/A YoY), and the annual figure for FY2022 was $1.9 million, up 48475.0%.
Capital Expenditures for Q3 2022 was $20000.0 at Atea Pharmaceuticals, down from $1.2 million in the prior quarter.
Over the last five years, Capital Expenditures for AVIR hit a ceiling of $1.2 million in Q2 2022 and a floor of $5000.0 in Q4 2020.